BRPI0717411A2 - Uso de inibidores de iap - Google Patents
Uso de inibidores de iapInfo
- Publication number
- BRPI0717411A2 BRPI0717411A2 BRPI0717411-0A2A BRPI0717411A BRPI0717411A2 BR PI0717411 A2 BRPI0717411 A2 BR PI0717411A2 BR PI0717411 A BRPI0717411 A BR PI0717411A BR PI0717411 A2 BRPI0717411 A2 BR PI0717411A2
- Authority
- BR
- Brazil
- Prior art keywords
- iap inhibitors
- iap
- inhibitors
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86215506P | 2006-10-19 | 2006-10-19 | |
US86216106P | 2006-10-19 | 2006-10-19 | |
PCT/US2007/022125 WO2008057172A2 (en) | 2006-10-19 | 2007-10-17 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0717411A2 true BRPI0717411A2 (pt) | 2013-11-12 |
Family
ID=39364966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0717411-0A2A BRPI0717411A2 (pt) | 2006-10-19 | 2007-10-17 | Uso de inibidores de iap |
Country Status (10)
Country | Link |
---|---|
US (1) | US20100316573A1 (pt) |
EP (1) | EP2076778A2 (pt) |
JP (1) | JP2010507096A (pt) |
KR (1) | KR20090082221A (pt) |
AU (1) | AU2007318220A1 (pt) |
BR (1) | BRPI0717411A2 (pt) |
CA (1) | CA2665838A1 (pt) |
MX (1) | MX2009004061A (pt) |
RU (1) | RU2009118487A (pt) |
WO (1) | WO2008057172A2 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005274937B2 (en) | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
EP1851200B1 (en) | 2005-02-25 | 2014-01-15 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
JP2009512719A (ja) | 2005-10-25 | 2009-03-26 | アエゲラ セラピューティクス インコーポレイテッド | Iapbirドメイン結合化合物 |
MX2008008191A (es) | 2005-12-20 | 2008-11-04 | Novartis Ag | Combinacion de un inhibidor iap y un taxano 7. |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
US8163792B2 (en) | 2006-05-16 | 2012-04-24 | Pharmascience Inc. | IAP BIR domain binding compounds |
JP5452223B2 (ja) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Iap阻害剤 |
BRPI0715195A2 (pt) | 2006-07-24 | 2013-06-11 | Tetralogic Pharm Corp | composto, mÉtodos para induzir e para estimular a apoptose em uma cÉlula, para intensificar a apoptose de cÉlulas patogÊnicas in vivo em um indivÍduo, e para tratar uma doenÇa, e, composiÇço farmacÊutica |
WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008137930A1 (en) * | 2007-05-07 | 2008-11-13 | Tetralogic Pharmaceuticals Corp. | TNFα GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS |
KR20110022608A (ko) * | 2008-05-16 | 2011-03-07 | 노파르티스 아게 | Iap 저해물질에 의한 면역조절 |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
US20120196793A1 (en) * | 2009-09-18 | 2012-08-02 | Firestone Brant G | Biomarkers for iap inhibitor compounds |
ES2625637T3 (es) | 2010-02-12 | 2017-07-20 | Pharmascience Inc. | Compuestos de unión al dominio BIR IAP |
UY33236A (es) * | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
CA2871995A1 (en) | 2012-05-04 | 2013-11-07 | Novartis Ag | Biomarkers for iap inhibitor therapy |
GB201305376D0 (en) * | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
KR102166292B1 (ko) * | 2018-11-13 | 2020-10-15 | 국민대학교 산학협력단 | 퀴논계 화합물을 유효성분으로 포함하는 피부 미백용 조성물 및 그 화합물의 스크리닝 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007523061A (ja) * | 2004-01-16 | 2007-08-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Smacペプチドミメティクスおよびその使用法 |
DK2253614T3 (da) * | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP-inhibitorer |
PE20110224A1 (es) * | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
-
2007
- 2007-10-17 KR KR1020097009957A patent/KR20090082221A/ko not_active Application Discontinuation
- 2007-10-17 RU RU2009118487/15A patent/RU2009118487A/ru not_active Application Discontinuation
- 2007-10-17 US US12/446,430 patent/US20100316573A1/en not_active Abandoned
- 2007-10-17 EP EP07867238A patent/EP2076778A2/en not_active Withdrawn
- 2007-10-17 MX MX2009004061A patent/MX2009004061A/es not_active Application Discontinuation
- 2007-10-17 CA CA002665838A patent/CA2665838A1/en not_active Abandoned
- 2007-10-17 WO PCT/US2007/022125 patent/WO2008057172A2/en active Application Filing
- 2007-10-17 AU AU2007318220A patent/AU2007318220A1/en not_active Abandoned
- 2007-10-17 BR BRPI0717411-0A2A patent/BRPI0717411A2/pt not_active IP Right Cessation
- 2007-10-17 JP JP2009533355A patent/JP2010507096A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2009118487A (ru) | 2010-11-27 |
JP2010507096A (ja) | 2010-03-04 |
US20100316573A1 (en) | 2010-12-16 |
AU2007318220A1 (en) | 2008-05-15 |
MX2009004061A (es) | 2009-04-27 |
WO2008057172A3 (en) | 2008-09-12 |
KR20090082221A (ko) | 2009-07-29 |
CA2665838A1 (en) | 2008-05-15 |
EP2076778A2 (en) | 2009-07-08 |
WO2008057172A2 (en) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0717411A2 (pt) | Uso de inibidores de iap | |
NO2021010I1 (no) | telostritat ethyl | |
CR10831A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
DOP2007000084A (es) | Derivados de dihidropirazolopirimidinona | |
DK2041138T3 (da) | Pyrroltriazinkinase-inhibitorer | |
DK2024375T3 (da) | Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere | |
BRPI0915231A2 (pt) | compostos inibidores de quinase e métodos de uso | |
BRPI0716327A2 (pt) | Composto de fenilpropionamida e uso | |
DK1940839T3 (da) | Pyridopyrimidione Inhibitors of P13Ka | |
ATE483711T1 (de) | Spiroindolinonderivate | |
NO345061B1 (no) | Anvendelse av DPP-IV inhibitorer | |
ATE469905T1 (de) | Pyridopyrimidinonderivate | |
DK2253614T3 (da) | IAP-inhibitorer | |
DK1778718T3 (da) | Iap-inhibitorer | |
ATE512135T1 (de) | Spiroindolinonderivate | |
DK1851200T3 (da) | Dimere iap-inhibitorer | |
DK2035394T3 (da) | 2-pyrazincarboxamidderivater | |
BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
CR10478A (es) | Amino-piperidine derivatives as cetp inhibitors | |
CR10562A (es) | Nuevos derivados de piridazina | |
FI20065757A (fi) | Beta-laktamaasin käyttö | |
BRPI0911332A2 (pt) | composições e uso de inibidores de epas1 | |
BRPI0922344A2 (pt) | inibidores de tfpi e métodos de uso | |
SMT201500218B (it) | Composti aril-fenil-solfonammido-cicloalchile e loro uso | |
BRPI0720547A2 (pt) | Inibidores de metaloprotease derivada de heterocíclico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A, 6A E 7A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |